Compare Ascendis Pharma A/S (ASND) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares MSCI India ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares MSCI India ETF trades at $48.74. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| ASND | INDA | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $55.29 |
52-Week Low | $163.32 | $45.42 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
INDA, the iShares MSCI India ETF, trades at $49.30 with a slight 0.57% daily gain amid a predominantly bearish technical outlook. The ETF faces mixed sentiment with India's strong 7.8% GDP growth (CNBC, 2026-06-05) contrasting with sectoral challenges in IT and clean energy. Technical indicators show neutral oscillators but bearish moving averages, with all support and resistance levels clustered around $49.
The outlook remains cautious due to macroeconomic risks from Middle East conflicts and domestic sector pressures. However, India's position as the fastest-growing large economy and analyst price targets suggesting upside potential (Seeking Alpha, 2026-06-03) offer long-term opportunities amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
